Nutriband Reports $2.04 Million Revenue with Net Loss of $8.23 Million for Fiscal Year Ending January 31, 2026

Nutriband Inc. reported a revenue of $2.04 million for the fiscal year ending January 31, 2026, a slight decrease from $2.14 million in the previous year. The company's cost of revenue also increased, leading to a gross profit of $566,308, down from $743,317 in the prior year. The decline in gross profit is attributed to lower margins on tape sales, while the Pocono Pharmaceuticals segment's revenue remained relatively stable. The company incurred a net loss of $8.23 million for the year, compared to a loss of $10.48 million in the previous year, reflecting improvements in operational efficiency despite ongoing challenges.

In terms of strategic developments, Nutriband has focused on its lead product, the AVERSA™ Fentanyl transdermal system, which is designed to deter opioid abuse. The company has engaged in a commercial development and clinical supply agreement with Kindeva Drug Delivery, which is expected to enhance the manufacturing process for AVERSA™ Fentanyl. Additionally, Nutriband has expanded its product pipeline to include AVERSA™ Buprenorphine and AVERSA™ Methylphenidate, both of which are in early stages of development. The company is also actively pursuing FDA approval for its products, with a planned 505(b)(2) NDA submission for AVERSA™ Fentanyl.

Operationally, Nutriband's workforce has remained stable, with a total employee count of approximately 12 as of January 31, 2026. The company has not reported significant changes in customer counts or user statistics, but it continues to focus on enhancing its market presence in the United States. The company’s manufacturing facility in Cherryville, North Carolina, is expected to support its growth as it ramps up production capabilities for its transdermal products.

Looking ahead, Nutriband anticipates an increase in demand for its products, particularly as it progresses through the FDA approval process. The company has indicated that it will require approximately $13 million for research and development of its AVERSA™ Fentanyl product, which includes clinical trials and manufacturing costs. Management believes that sufficient funds will be generated from operations to support its activities over the next year, although it acknowledges the inherent risks associated with drug development and regulatory approval processes. The company remains committed to addressing the opioid crisis through its innovative product offerings while navigating the complexities of the pharmaceutical market.